JO3041B1 - مركبات جديدة مفيدة لمعالجة الأمراض التنكسية والالتهابية - Google Patents
مركبات جديدة مفيدة لمعالجة الأمراض التنكسية والالتهابيةInfo
- Publication number
- JO3041B1 JO3041B1 JOP/2009/0259A JOP20090259A JO3041B1 JO 3041 B1 JO3041 B1 JO 3041B1 JO P20090259 A JOP20090259 A JO P20090259A JO 3041 B1 JO3041 B1 JO 3041B1
- Authority
- JO
- Jordan
- Prior art keywords
- diseases
- disease
- treatment
- cartilage
- involving
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
Abstract
يوضح الاختراع الحالي مركب مبتكر من (1 ،2 ،3) تراي ازولو (1،5، a) بيريدين ويحمل الصيغة التي تتمثل بما يلي : يمكن تحضير هذا المركب على اساس انه مركب دوائي ويمكن ان يستخدم في علاج عدد من الحالات المرضية والوقاية منها لدى الثدييات بما في ذلك الانسان وتشمل على سبيل المثال لا الحصر الامراض المتعلقة بالتاكل الغضروفي و/او العظام على سبيل المثال هشاشة العظام و او الحالات المرتبطة باستجابات المناعة والالتهابات مثل مرض كرون ومرض التهاب المفاصل الروماتيزمي و الصدفية ومرض التهاب المجاري التنفسية التحسية مثل الربو والتهاب الجيوب الانفية، والتهاب المفاصل مجهول السبب والتهاب القولون وامراض التهاب المعدة وحالات امراض الوهن الداخلي( مثل التعقيدات المصاحبة لما بعد العمليات الجراحية او الحالات المتعلقة بالوهن المزمن والمساهمه على سبيل المثال امراض قصور القلب المزمنة) امراض تتعلق بخلل في الغضروف وانتكاسه( مثل امراض متعلقة بتحفيز بناء الخلايا الغضروفية ) والتشوهات الخلفية للغضروف والامراض المتعلقة برفض الزراعه ومستقبل انترلوكين (6) IL6 ( على سبيل المثال رفض زراعة الاعضاء
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13592008P | 2008-07-25 | 2008-07-25 | |
US22068509P | 2009-06-26 | 2009-06-26 |
Publications (1)
Publication Number | Publication Date |
---|---|
JO3041B1 true JO3041B1 (ar) | 2016-09-05 |
Family
ID=41021059
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JOP/2009/0259A JO3041B1 (ar) | 2008-07-25 | 2009-07-12 | مركبات جديدة مفيدة لمعالجة الأمراض التنكسية والالتهابية |
Country Status (36)
Country | Link |
---|---|
US (5) | US8242274B2 (ar) |
EP (2) | EP2361251B1 (ar) |
JP (2) | JP5480261B2 (ar) |
KR (2) | KR101711911B1 (ar) |
CN (2) | CN102105472B (ar) |
AR (1) | AR072875A1 (ar) |
AU (2) | AU2009273143B2 (ar) |
BR (2) | BRPI0916659B8 (ar) |
CA (2) | CA2730757A1 (ar) |
CL (1) | CL2009001637A1 (ar) |
CO (1) | CO6361925A2 (ar) |
CR (1) | CR20110092A (ar) |
CY (2) | CY1113945T1 (ar) |
DK (2) | DK2346864T3 (ar) |
DO (1) | DOP2011000022A (ar) |
EA (2) | EA018587B1 (ar) |
ES (2) | ES2406691T3 (ar) |
HK (2) | HK1158635A1 (ar) |
HR (2) | HRP20130357T1 (ar) |
IL (2) | IL210262A (ar) |
JO (1) | JO3041B1 (ar) |
MA (1) | MA32551B1 (ar) |
ME (1) | ME02046B (ar) |
MX (2) | MX2011000756A (ar) |
MY (1) | MY157615A (ar) |
NZ (1) | NZ590646A (ar) |
PE (1) | PE20100152A1 (ar) |
PL (2) | PL2361251T3 (ar) |
PT (2) | PT2361251E (ar) |
RS (2) | RS53406B (ar) |
SI (2) | SI2346864T1 (ar) |
SM (2) | SMT201300051B (ar) |
TW (1) | TWI447118B (ar) |
UY (1) | UY32006A (ar) |
WO (2) | WO2010010191A1 (ar) |
ZA (2) | ZA201100396B (ar) |
Families Citing this family (72)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0719803D0 (en) | 2007-10-10 | 2007-11-21 | Cancer Rec Tech Ltd | Therapeutic compounds and their use |
JO3041B1 (ar) * | 2008-07-25 | 2016-09-05 | Galapagos Nv | مركبات جديدة مفيدة لمعالجة الأمراض التنكسية والالتهابية |
MX2011012961A (es) | 2009-06-05 | 2012-01-30 | Cephalon Inc | Preparacion y usos de derivados de 1,2,4-triazolo[1,5a]-piridina. |
TWI462920B (zh) | 2009-06-26 | 2014-12-01 | 葛萊伯格有限公司 | 用於治療退化性及發炎疾病之新穎化合物 |
CA2708690A1 (en) * | 2009-06-26 | 2010-12-26 | Markus Braun | Process for producing cellulose beads from solutions of cellulose in ionic liquid |
JO3030B1 (ar) * | 2009-06-26 | 2016-09-05 | Galapagos Nv | مركب جديد مفيد لمعالجة الامراض التنكسية والالتهابات |
EP2566333A4 (en) | 2010-05-07 | 2014-04-02 | Univ Leland Stanford Junior | IDENTIFICATION OF STABILIZERS OF MULTIMEDER PROTEINS |
US20130143915A1 (en) | 2010-07-01 | 2013-06-06 | Cellzome Limited | Triazolopyridines as tyk2 inhibitors |
AR086042A1 (es) * | 2011-04-28 | 2013-11-13 | Galapagos Nv | Compuesto util para el tratamiento de enfermedades degenerativas e inflamatorias y composicion farmaceutica |
CN104797267A (zh) | 2012-06-26 | 2015-07-22 | 德玛医药 | 使用卫康醇、二乙酰二脱水卫矛醇、二溴卫矛醇或类似物或其衍生物治疗具有基因多型性或ahi1失调或突变患者的抗酪氨酸激酶抑制剂的恶性肿瘤的方法 |
US9169214B2 (en) | 2012-12-21 | 2015-10-27 | The Board Of Trustees Of The Leland Stanford Junior University | Compounds and compositions that bind and stabilize transthyretin and their use for inhibiting transthyretin amyloidosis and protein-protein interactions |
CN103965114B (zh) * | 2013-01-28 | 2016-01-06 | 苏州泽璟生物制药有限公司 | 氘代的苯基氨基嘧啶化合物以及包含该化合物的药物组合物 |
US20160123982A1 (en) | 2013-02-04 | 2016-05-05 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for assaying jak2 activity in red blood cells and uses thereof |
CN105339370B (zh) * | 2013-06-19 | 2017-09-15 | 加拉帕戈斯股份有限公司 | 用于治疗炎症性疾病的化合物和及其药物组合物 |
ES2841137T3 (es) | 2013-12-20 | 2021-07-07 | Sagimet Biosciences Inc | Moduladores heterocíclicos de la síntesis de lípidos y combinaciones de los mismos |
GB201402071D0 (en) * | 2014-02-07 | 2014-03-26 | Galapagos Nv | Novel salts and pharmaceutical compositions thereof for the treatment of inflammatory disorders |
GB201402070D0 (en) | 2014-02-07 | 2014-03-26 | Galapagos Nv | Pharmaceutical compositions for the treatment of inflammatory disorders |
WO2016025129A1 (en) | 2014-08-14 | 2016-02-18 | Alhamadsheh Mamoun M | Conjugation of pharmaceutically active agents with transthyretin ligands through adjustable linkers to increase serum half-life |
TWI679205B (zh) | 2014-09-02 | 2019-12-11 | 日商日本新藥股份有限公司 | 吡唑并噻唑化合物及醫藥 |
CN107428749B (zh) | 2015-01-28 | 2020-07-24 | 上海复旦张江生物医药股份有限公司 | 取代的咪唑并[1,2-α]吡啶-2-基胺化合物及其药物组合物和使用方法 |
WO2016165953A1 (en) * | 2015-04-13 | 2016-10-20 | Galapagos Nv | Methods for the treatment of inflammatory disorders |
JP6600365B2 (ja) * | 2015-04-29 | 2019-10-30 | 无▲錫▼福祈制▲薬▼有限公司 | Jak阻害剤 |
WO2016179207A1 (en) * | 2015-05-05 | 2016-11-10 | Concert Pharmaceuticals, Inc. | Deuterated filgotinib |
CN105061420B (zh) * | 2015-06-04 | 2017-09-05 | 南京旗昌医药科技有限公司 | 一种jak抑制剂的晶型及其制备方法和应用 |
CN104987333B (zh) * | 2015-07-14 | 2017-01-11 | 苏州富士莱医药股份有限公司 | 一种Filgotinib的合成方法 |
WO2017012771A1 (en) | 2015-07-23 | 2017-01-26 | Ratiopharm Gmbh | Crystalline filgotinib sulfonic acid addition salts |
WO2017012773A1 (en) | 2015-07-23 | 2017-01-26 | Ratiopharm Gmbh | Solid forms of filgotinib free base |
WO2017012770A1 (en) | 2015-07-23 | 2017-01-26 | Ratiopharm Gmbh | Acid addition salts of filgotinib |
CN105111206B (zh) * | 2015-09-18 | 2017-07-25 | 上海宣创生物科技有限公司 | 一种环丙烷甲酰胺衍生物e晶型及其制备方法 |
CN105198877B (zh) * | 2015-09-18 | 2017-09-22 | 上海宣创生物科技有限公司 | 一种环丙烷甲酰胺衍生物g晶型及其制备方法 |
CN105198879B (zh) * | 2015-09-18 | 2017-09-22 | 上海宣创生物科技有限公司 | 一种环丙烷甲酰胺衍生物c晶型及其制备方法 |
CN105198878B (zh) * | 2015-09-18 | 2017-07-25 | 上海宣创生物科技有限公司 | 一种环丙烷甲酰胺衍生物f晶型及其制备方法 |
CN105218539B (zh) * | 2015-09-18 | 2017-07-25 | 上海宣创生物科技有限公司 | 一种环丙烷甲酰胺衍生物b晶型及其制备方法 |
CN105111207B (zh) * | 2015-09-18 | 2017-07-25 | 上海宣创生物科技有限公司 | 一种环丙烷甲酰胺衍生物d晶型及其制备方法 |
CN105198880B (zh) * | 2015-09-18 | 2017-07-25 | 上海宣创生物科技有限公司 | 一种环丙烷甲酰胺衍生物a晶型及其制备方法 |
CN105198876B (zh) * | 2015-09-18 | 2017-09-29 | 上海宣创生物科技有限公司 | 一种环丙烷甲酰胺衍生物h晶型及其制备方法 |
CN108349974B (zh) * | 2016-02-02 | 2021-04-30 | 深圳市塔吉瑞生物医药有限公司 | 一种取代的吡啶酰胺类化合物及其应用 |
TWI712604B (zh) | 2016-03-01 | 2020-12-11 | 日商日本新藥股份有限公司 | 具jak抑制作用之化合物之結晶 |
CN109843883B (zh) * | 2016-07-26 | 2022-01-14 | 苏州隆博泰药业有限公司 | 作为选择性jak抑制剂化合物,该化合物的盐类及其治疗用途 |
JOP20190024A1 (ar) | 2016-08-26 | 2019-02-19 | Gilead Sciences Inc | مركبات بيروليزين بها استبدال واستخداماتها |
CN107880038B (zh) * | 2016-09-30 | 2021-09-28 | 中国医药研究开发中心有限公司 | [1,2,4]三唑并[1,5-a]吡啶类化合物及其制备方法和医药用途 |
JOP20190077A1 (ar) * | 2016-10-10 | 2019-04-09 | Array Biopharma Inc | مركبات بيرازولو [1، 5-a]بيريدين بها استبدال كمثبطات كيناز ret |
AU2017350688B2 (en) * | 2016-10-26 | 2021-04-01 | Rapport Therapeutics, Inc. | Fused azaheterocyclic compounds and their use as AMPA receptor modulators |
CN109963851B (zh) * | 2016-10-26 | 2021-11-30 | 詹森药业有限公司 | 融合的双环吡啶化合物及其作为ampa受体调节剂的用途 |
EA039352B1 (ru) * | 2017-01-19 | 2022-01-17 | Сучжоу Лонгбайотек Фармасьютикалз Ко., Лтд. | Соединение в качестве селективного ингибитора jak и его соли и терапевтическое применение |
CN108341814B (zh) * | 2017-01-23 | 2021-09-03 | 上海翔锦生物科技有限公司 | Jak激酶抑制剂及其应用 |
MX2019009764A (es) | 2017-02-17 | 2019-11-11 | Eidos Therapeutics Inc | Procesos para preparar acido 3-(3-(3,5-dimetil-1h-pirazol-4-il)pro poxi)-4- 5-fluorobenzoico (ag-10), sus compuestos intermedios, y sales del mismo. |
GB201702603D0 (en) | 2017-02-17 | 2017-04-05 | Galápagos Nv | Novel compositions and pharmaceutical compositions thereof for the treatment of inflammatory disorders |
WO2018167283A1 (en) | 2017-03-17 | 2018-09-20 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for the diagnosis and treatment of pancreatic ductal adenocarcinoma associated neural remodeling |
EP3610264A1 (en) | 2017-04-13 | 2020-02-19 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for the diagnosis and treatment of pancreatic ductal adenocarcinoma |
US11427581B2 (en) | 2018-01-31 | 2022-08-30 | Zhuhai United Laboratories Co., Ltd. | JAK inhibitor and use thereof |
EP3759109B1 (en) | 2018-02-26 | 2023-08-30 | Gilead Sciences, Inc. | Substituted pyrrolizine compounds as hbv replication inhibitors |
CA3090545A1 (en) | 2018-02-28 | 2019-09-06 | University Of Southern California | Compositions and methods for modulating inflammatory and degenerative disorder |
EP3768841A4 (en) | 2018-03-23 | 2021-12-08 | Eidos Therapeutics, Inc. | METHODS OF TREATING TTR AMYLOSIS USING AG10 |
BR112020026493A2 (pt) | 2018-08-17 | 2021-03-23 | Eidos Therapeutics, Inc. | Formulações de ag10 |
WO2020038457A1 (zh) * | 2018-08-23 | 2020-02-27 | 珠海联邦制药股份有限公司 | 作为JAK抑制剂的[1,2,4]三唑并[1,5-a]吡啶类化合物及其应用 |
US10815227B2 (en) | 2018-08-27 | 2020-10-27 | Cadila Healthcare Limited | Processes for the preparation of filgotinib |
WO2020092015A1 (en) | 2018-11-02 | 2020-05-07 | University Of Rochester | Therapeutic mitigation of epithelial infection |
US20230391768A2 (en) * | 2018-11-07 | 2023-12-07 | Dana-Farber Cancer Institute, Inc. | Imidazopyridine derivatives and aza-imidazopyridine derivatives as janus kinase 2 inhibitors and uses thereof |
US11633399B2 (en) | 2018-12-25 | 2023-04-25 | Sol-Gel Technologies Ltd. | Treatment of skin disorders with compositions comprising an EGFR inhibitor |
AU2020311940A1 (en) | 2019-07-11 | 2022-02-03 | ESCAPE Bio, Inc. | Indazoles and azaindazoles as LRRK2 inhibitors |
CN111892592B (zh) * | 2019-08-06 | 2023-09-19 | 江苏柯菲平医药股份有限公司 | Jak激酶抑制剂及其用途 |
CN111072655B (zh) * | 2019-12-30 | 2021-12-10 | 深圳市坤健创新药物研究院 | 一种三氮唑并吡啶类化合物及其制备方法和药用组合物与应用 |
KR20220127900A (ko) * | 2020-02-13 | 2022-09-20 | 주하이 유나이티드 라보라토리즈 컴퍼니 리미티드 | Jak 키나아제 관련 질병의 치료를 위한 약물의 제조에 있어서 jak 억제제의 용도 |
US20230091250A1 (en) * | 2020-02-21 | 2023-03-23 | Zhuhai United Laboratories Co., Ltd. | Crystalline form of jak inhibitor and application thereof |
WO2021226261A1 (en) | 2020-05-06 | 2021-11-11 | Ajax Therapeutics, Inc. | 6-heteroaryloxy benzimidazoles and azabenzimidazoles as jak2 inhibitors |
CN111617318B (zh) * | 2020-05-26 | 2021-12-10 | 南京市儿童医院 | 可注射型儿童骺板再生水凝胶的制备方法 |
CN114394965B (zh) * | 2021-01-29 | 2023-09-12 | 深圳市乐土生物医药有限公司 | 三唑并吡啶类化合物及其制备方法与用途 |
CN113773322B (zh) * | 2021-11-10 | 2022-02-11 | 奥锐特药业(天津)有限公司 | 一种Filgotinib的制备方法 |
CN116496268A (zh) * | 2022-01-18 | 2023-07-28 | 盛世泰科生物医药技术(苏州)有限公司 | 一种含环丙酰胺化合物及其应用 |
US11596612B1 (en) | 2022-03-08 | 2023-03-07 | PTC Innovations, LLC | Topical anesthetics |
US11746108B1 (en) * | 2022-06-13 | 2023-09-05 | Apm Therapeutics 1, Inc. | Triazolopyridine polymorph A |
Family Cites Families (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6500854B1 (en) | 1999-01-29 | 2002-12-31 | Chugai Sei Yaku Kabushiki Kaisha | Chondrongenesis promotors and indolin-2-one derivatives |
US20040138285A1 (en) | 2001-04-27 | 2004-07-15 | Makoto Okazaki | Chondrogenesis promoters |
US6514989B1 (en) * | 2001-07-20 | 2003-02-04 | Hoffmann-La Roche Inc. | Aromatic and heteroaromatic substituted 1,2,4-triazolo pyridine derivatives |
WO2004072072A1 (en) | 2003-02-14 | 2004-08-26 | Pfizer Products Inc. | Triazolo-pyridines as anti-inflammatory compounds |
TWI221602B (en) * | 2003-07-21 | 2004-10-01 | Benq Corp | Emergent disc-withdrawing apparatus |
US20050222171A1 (en) | 2004-01-22 | 2005-10-06 | Guido Bold | Organic compounds |
EP2386856B1 (en) | 2004-06-21 | 2013-07-24 | Galapagos N.V. | Methods and means for treatment of osteoarthritis |
EP1786811A2 (en) | 2004-08-18 | 2007-05-23 | Pharmacia & Upjohn Company LLC | Triazolopyridine compounds |
MX2007004179A (es) | 2004-10-07 | 2007-06-07 | Warner Lambert Co | Derivados de triazolpiridina como agentes antibacterianos. |
GB0515026D0 (en) * | 2005-07-21 | 2005-08-31 | Novartis Ag | Organic compounds |
CA2662074A1 (en) * | 2006-08-30 | 2008-03-06 | Cellzome Limited | Triazole derivatives as kinase inhibitors |
ATE495743T1 (de) * | 2006-12-01 | 2011-02-15 | Galapagos Nv | Triazolopyridinverbindungen zur behandlung von degenerations- und entzündungskrankheiten |
PE20090370A1 (es) * | 2007-06-05 | 2009-04-30 | Takeda Pharmaceutical | Derivados de heterociclo fusionado como inhibidores de quinasa |
EA201000130A1 (ru) * | 2007-07-18 | 2010-08-30 | Новартис Аг | Бициклические гетероарильные соединения и их применение в качестве ингибиторов киназы |
WO2009017954A1 (en) | 2007-08-01 | 2009-02-05 | Phenomix Corporation | Inhibitors of jak2 kinase |
CA2691448A1 (en) * | 2007-08-31 | 2009-03-05 | Dominique Swinnen | Triazolopyridine compounds and their use as ask inhibitors |
GB0719803D0 (en) * | 2007-10-10 | 2007-11-21 | Cancer Rec Tech Ltd | Therapeutic compounds and their use |
US9088430B2 (en) * | 2008-02-19 | 2015-07-21 | Qualcomm Incorporated | Providing network originated push messages for remotely testing a mobile device |
US20090217316A1 (en) * | 2008-02-22 | 2009-08-27 | Binita Gupta | Systems and Methods for Advertising Insertion Notification in a Real-Time Streaming Media Service |
RU2561104C2 (ru) | 2008-06-20 | 2015-08-20 | Дженентек, Инк. | Триазолопиридиновые соединения-ингибиторы jak и способы |
WO2010010188A1 (en) | 2008-07-25 | 2010-01-28 | Galapagos Nv | Novel compounds useful for the treatment of degenerative and inflammatory diseases. |
WO2010010184A1 (en) | 2008-07-25 | 2010-01-28 | Galapagos Nv | [1, 2, 4] triazolo [1, 5-a] pyridines as jak inhibitors |
WO2010010186A1 (en) | 2008-07-25 | 2010-01-28 | Galapagos Nv | Novel compounds useful for the treatment of degenerative and inflammatory diseases |
JO3041B1 (ar) | 2008-07-25 | 2016-09-05 | Galapagos Nv | مركبات جديدة مفيدة لمعالجة الأمراض التنكسية والالتهابية |
WO2010010187A1 (en) | 2008-07-25 | 2010-01-28 | Galapagos Nv | Novel compounds useful for the treatment of degenerative and inflammatory diseases |
WO2010010189A1 (en) | 2008-07-25 | 2010-01-28 | Galapagos Nv | Novel compounds useful for the treatment of degenerative and inflammatory diseases |
PT2391435E (pt) * | 2009-02-02 | 2014-01-23 | Basf Se | Agente de absorção contendo aminas cíclicas para a remoção de gases ácidos |
DE102009000543A1 (de) * | 2009-02-02 | 2010-08-12 | Evonik Degussa Gmbh | Verfahren, Absorptionsmedien und Vorrichtung zur Absorption von CO2 aus Gasmischungen |
MX2011012961A (es) | 2009-06-05 | 2012-01-30 | Cephalon Inc | Preparacion y usos de derivados de 1,2,4-triazolo[1,5a]-piridina. |
TWI462920B (zh) | 2009-06-26 | 2014-12-01 | 葛萊伯格有限公司 | 用於治療退化性及發炎疾病之新穎化合物 |
JO3030B1 (ar) | 2009-06-26 | 2016-09-05 | Galapagos Nv | مركب جديد مفيد لمعالجة الامراض التنكسية والالتهابات |
US20130310340A1 (en) | 2012-05-16 | 2013-11-21 | Rigel Pharmaceuticals, Inc. | Method of treating muscular degradation |
SI2863950T1 (sl) | 2012-06-22 | 2018-10-30 | Galapagos Nv | Aminotriazolopiridin za uporabo pri zdravljenju vnetja in njegovi farmacevtski sestavki |
-
2009
- 2009-07-12 JO JOP/2009/0259A patent/JO3041B1/ar active
- 2009-07-22 AR ARP090102793A patent/AR072875A1/es active IP Right Grant
- 2009-07-23 CL CL2009001637A patent/CL2009001637A1/es unknown
- 2009-07-23 TW TW098124908A patent/TWI447118B/zh active
- 2009-07-24 CN CN2009801291247A patent/CN102105472B/zh active Active
- 2009-07-24 JP JP2011519189A patent/JP5480261B2/ja active Active
- 2009-07-24 SI SI200930582T patent/SI2346864T1/sl unknown
- 2009-07-24 MX MX2011000756A patent/MX2011000756A/es active IP Right Grant
- 2009-07-24 PL PL09781072T patent/PL2361251T3/pl unknown
- 2009-07-24 WO PCT/EP2009/059605 patent/WO2010010191A1/en active Application Filing
- 2009-07-24 RS RS20140345A patent/RS53406B/en unknown
- 2009-07-24 AU AU2009273143A patent/AU2009273143B2/en active Active
- 2009-07-24 SI SI200930973T patent/SI2361251T1/sl unknown
- 2009-07-24 DK DK09781073.3T patent/DK2346864T3/da active
- 2009-07-24 WO PCT/EP2009/059604 patent/WO2010010190A1/en active Application Filing
- 2009-07-24 PL PL09781073T patent/PL2346864T3/pl unknown
- 2009-07-24 JP JP2011519188A patent/JP5559168B2/ja active Active
- 2009-07-24 BR BRPI0916659A patent/BRPI0916659B8/pt active IP Right Grant
- 2009-07-24 CA CA2730757A patent/CA2730757A1/en not_active Abandoned
- 2009-07-24 UY UY0001032006A patent/UY32006A/es active IP Right Grant
- 2009-07-24 BR BRPI0916862A patent/BRPI0916862B8/pt active IP Right Grant
- 2009-07-24 CN CN200980129088.4A patent/CN102105471B/zh active Active
- 2009-07-24 EP EP09781072.5A patent/EP2361251B1/en active Active
- 2009-07-24 MY MYPI20093101A patent/MY157615A/en unknown
- 2009-07-24 ES ES09781073T patent/ES2406691T3/es active Active
- 2009-07-24 KR KR1020117004383A patent/KR101711911B1/ko active IP Right Grant
- 2009-07-24 CA CA2730762A patent/CA2730762C/en active Active
- 2009-07-24 ME MEP-2014-72A patent/ME02046B/me unknown
- 2009-07-24 KR KR1020117004384A patent/KR101676391B1/ko active IP Right Grant
- 2009-07-24 NZ NZ590646A patent/NZ590646A/en unknown
- 2009-07-24 RS RS20130214A patent/RS52823B/en unknown
- 2009-07-24 EA EA201170257A patent/EA018587B1/ru not_active IP Right Cessation
- 2009-07-24 MX MX2011000758A patent/MX2011000758A/es active IP Right Grant
- 2009-07-24 US US12/508,950 patent/US8242274B2/en active Active
- 2009-07-24 EP EP09781073A patent/EP2346864B1/en active Active
- 2009-07-24 PE PE2009000989A patent/PE20100152A1/es active IP Right Grant
- 2009-07-24 PT PT97810725T patent/PT2361251E/pt unknown
- 2009-07-24 DK DK09781072.5T patent/DK2361251T3/da active
- 2009-07-24 US US13/055,936 patent/US8853240B2/en active Active
- 2009-07-24 EA EA201170255A patent/EA018080B1/ru unknown
- 2009-07-24 AU AU2009273144A patent/AU2009273144B2/en active Active
- 2009-07-24 ES ES09781072.5T patent/ES2485913T3/es active Active
- 2009-07-24 PT PT97810733T patent/PT2346864E/pt unknown
-
2010
- 2010-12-26 IL IL210262A patent/IL210262A/en active IP Right Grant
- 2010-12-26 IL IL210261A patent/IL210261A/en active IP Right Grant
-
2011
- 2011-01-14 ZA ZA2011/00396A patent/ZA201100396B/en unknown
- 2011-01-18 ZA ZA2011/00472A patent/ZA201100472B/en unknown
- 2011-01-18 DO DO2011000022A patent/DOP2011000022A/es unknown
- 2011-02-11 MA MA33602A patent/MA32551B1/ar unknown
- 2011-02-16 CR CR20110092A patent/CR20110092A/es unknown
- 2011-02-24 CO CO11022531A patent/CO6361925A2/es active IP Right Grant
- 2011-11-30 HK HK11112990.2A patent/HK1158635A1/xx unknown
- 2011-11-30 HK HK11112985.9A patent/HK1158634A1/xx unknown
-
2012
- 2012-08-10 US US13/572,043 patent/US20120309784A1/en not_active Abandoned
-
2013
- 2013-04-23 HR HRP20130357AT patent/HRP20130357T1/hr unknown
- 2013-04-24 CY CY20131100335T patent/CY1113945T1/el unknown
- 2013-05-15 SM SM201300051T patent/SMT201300051B/xx unknown
-
2014
- 2014-06-17 SM SM201400072T patent/SMT201400072B/xx unknown
- 2014-07-15 HR HRP20140681AT patent/HRP20140681T1/hr unknown
- 2014-07-29 CY CY20141100572T patent/CY1115569T1/el unknown
- 2014-10-06 US US14/507,396 patent/US9415037B2/en active Active
-
2016
- 2016-08-15 US US15/236,578 patent/US10206907B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JO3041B1 (ar) | مركبات جديدة مفيدة لمعالجة الأمراض التنكسية والالتهابية | |
HRP20200033T1 (hr) | 5-fenil-[1,2,4]triazolo[1,5-a]piridin-2-il karboksamidi kao jak inhibitori | |
MX2014006980A (es) | Pirazol[1,5-a]piridina sustituida como inhibidores de la cinasa del receptor de tropomiosina (trk). | |
EA201171306A1 (ru) | ЗАМЕЩЕННЫЕ ПРОИЗВОДНЫЕ ИМИДАЗО[1,2-α]ПИРИДИНА, ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ И СПОСОБЫ ПРИМЕНЕНИЯ В КАЧЕСТВЕ ИНГИБИТОРОВ β-СЕКРЕТАЗЫ | |
WO2009043468A3 (en) | Use of corticotropin-releasing factor as a therapeutic agent | |
WO2009043465A3 (en) | Use of beta-endorphin as a therapeutic agent | |
WO2009040048A3 (en) | Use of the c-reactive peptide as a therapeutic agent | |
WO2009033732A3 (en) | Use of the peptide phpfhlfvy (renin inhibitor) as a therapeutic agent | |
WO2009033793A3 (en) | Pentagastrin as a therapeutic agent | |
MX355852B (es) | Compuestos de pirazolo [3,4-c] piridina y métodos de uso. | |
EA201290878A1 (ru) | ПРОИЗВОДНЫЕ ИМИДАЗО[1,2-a]ПИРАЗИНА И ИХ ПРИМЕНЕНИЕ ДЛЯ ПРОФИЛАКТИКИ ИЛИ ЛЕЧЕНИЯ НЕВРОЛОГИЧЕСКИХ, ПСИХИАТРИЧЕСКИХ И МЕТАБОЛИЧЕСКИХ РАССТРОЙСТВ И ЗАБОЛЕВАНИЙ | |
WO2009033739A3 (en) | Use of a peptide as a therapeutic agent | |
DK1718649T3 (da) | Imidazo[1,2-c]pyrimidinyleddikesyrederivater | |
EA201070929A1 (ru) | ФУРО- И ТИЕНО[3,2-c]ПИРИДИНЫ | |
WO2009049742A3 (en) | Use of melanotrophin-potentiating factor as a therapeutic agent | |
WO2009033723A3 (en) | Use of aip2 as a therapeutic agent | |
NO20090171L (no) | Substituerte aminopyrazolpyridiner og salter derav, fremgangsmate for fremstilling av slike, og farmasoytiske preparater inneholdende slike | |
MX2020003863A (es) | Compuestos novedosos y composiciones farmaceuticas de los mismos para el tratamiento de trastornos inflamatorios. | |
WO2010092015A8 (en) | Urea triazolo [1, 5-a] pyridine derivatives as pi3k inhibitors | |
WO2009046860A3 (en) | Use of dago as a therapeutic agent | |
UA103036C2 (ru) | [1,2,4]ТРИАЗОЛО[1,5-а]ПИРИДИН, ПРИЕМЛЕМЫЙ ДЛЯ ЛЕЧЕНИЯ ДЕГЕНЕРАТИВНЫХ И ВОСПАЛИТЕЛЬНЫХ ЗАБОЛЕВАНИЙ | |
NZ601998A (en) | Substituted aza-bicyclic imidazole derivatives useful as trpm8 receptor modulators | |
GB201318158D0 (en) | Compositions,process of preparation of said compositions and method of treating inflammatory diseases | |
WO2010147947A3 (en) | NOVEL [3,2-c] HETEROARYL STEROIDS AS GLUCOCORTICOID RECEPTOR AGONISTS, COMPOSITIONS AND USES THEREOF | |
TH124149B (th) | สารประกอบชนิดใหม่ที่มีประโยชน์สำหรับการรักษาโรคที่มีการเสื่อมสภาพและ มีการอักเสบ |